Icosavax set for best day on promising data from RSV vaccine trial

Icosavax

14/12/2022 19:43

** Shares of biopharma company Icosavax Inc  ICVX.O  jump
58% to $6.63, set for biggest ever one-day pct gain
    ** ICVX among top pct gainers across U.S. exchanges
    ** Company late Tuesday provided data from early-stage trial
of its experimental RSV vaccine IVX-121, which showed
neutralizing antibody response against RSV lasted for at least
six months after one dose
    ** Respiratory syncytial virus (RSV) is a common, contagious
virus that causes infections of the respiratory tract
    ** Cowen and Co says durability data in older adults
compares favorably to RSV vaccines from Pfizer Inc  PFE.N  and
GSK  GSK.L 
    ** Despite session gains, Icosavax shares down ~73.6% YTD
 (Reporting by Mariam E Sunny)
 ((Mariam.ESunny@thomsonreuters.com))